ADAM21P1

Across TCGA pan-cancer cohorts, ADAM21P1 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated ADAM21P1 data layer compared with 8 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher ADAM21P1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ADAM21P1 expression acts as an unfavorable survival marker, although some lineages such as UCS and BRCA show a favorable association.

MESO, DLBC, and UCS are the cancer types where ADAM21P1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.397	0.640	<.001	135	view →
DLBC	DFS	Quartile	II,III,IV	0.065	0.874	<.001	39	view →
UCS	DFS	Quartile	III,IV	0.619	0.170	.017	28	view →
READ	DFS	Tertile	IV	0.176	0.639	.003	18	view →
TGCT	DFS	Tertile	II,III,IV	0.674	1.000	.007	12	view →
SKCM	DFS	Tertile	IV	0.046	0.518	.003	10	view →
PAAD	DFS	Tertile	III,IV	0.152	0.821	.045	9	view →
BRCA	OS	Median	II,III,IV	0.969	0.947	.022	8	view →
LIHC	DFS	Median	All	0.171	0.321	.045	8	view →
LUSC	OS	Tertile	III,IV	0.566	0.328	.035	5	view →
SARC	DFS	Tertile	All	0.405	0.596	.015	5	view →
ESCA	OS	Tertile	All	0.782	0.610	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

ADAM21P1–MESO (OS)

Open the MESO breakdown →